Scancell confirms Neuphoria reverse-merger talks as SCLP targets Nasdaq and Phase 3 funding

Scancell Holdings plc (AIM: SCLP) has confirmed advanced discussions to acquire Nasdaq-listed Neuphoria Therapeutics Inc. (Nasdaq: NEUP) through an all-share reverse-merger transaction that could give the British immuno-oncology company a United States listing. Scancell Holdings is simultaneously negotiating equity and debt financing for a global Phase 3 registrational study of iSCIB1+ in advanced melanoma. The proposed transaction would combine Scancell Holdings’ late-stage oncology pipeline with Neuphoria Therapeutics’ Nasdaq platform and US$19.4 million cash balance, although the exchange ratio, financing size and final ownership structure remain undisclosed. SCLP closed 3.2% lower at 18.4 pence on June 26, valuing Scancell Holdings at approximately £191 million as investors weighed improved access to United States capital against potentially substantial dilution and transaction risk.

Why could acquiring Neuphoria Therapeutics be faster than pursuing a standalone Nasdaq listing?

Scancell Holdings has reached the stage where its capital-market structure matters almost as much as its science. A multinational registrational trial requires significantly more capital, operational infrastructure and investor support than the earlier Phase 2 programme, while AIM alone may not provide sufficient specialist demand on attractive terms.

Acquiring Neuphoria Therapeutics could allow Scancell Holdings to enter Nasdaq through an existing public-company structure rather than completing a conventional United States initial public offering. A traditional listing would require extensive preparation, marketing, underwriting and market timing, with no guarantee that sufficient investor demand would be available when the company needs to begin its Phase 3 programme.

Neuphoria Therapeutics already reports under United States securities rules and has a Nasdaq-listed share class. The transaction could therefore provide Scancell Holdings with a United States trading platform, an established corporate reporting framework and direct access to specialist biotechnology investors familiar with late-stage clinical risk.

The process will not be automatic or inexpensive. Scancell Holdings and Neuphoria Therapeutics must agree an exchange ratio, complete due diligence, prepare transaction documents, obtain shareholder and regulatory approvals, satisfy Nasdaq requirements and determine whether the existing AIM quotation will be retained alongside the United States listing.

The company has stated that the potential acquisition is not expected to constitute a reverse takeover under the AIM Rules. It is nevertheless being described as a reverse merger because the economically larger clinical business would obtain access to Neuphoria Therapeutics’ United States public listing through the acquisition.

The strategic logic is therefore clear. Scancell Holdings needs more capital and broader institutional visibility before starting a pivotal study, while Neuphoria Therapeutics needs a new operating strategy after its lead programme suffered a Phase 3 failure. Each company has something the other currently lacks.

What does Neuphoria Therapeutics contribute after its Phase 3 anxiety trial failed?

Neuphoria Therapeutics was previously focused on BNC210, an experimental treatment developed for social anxiety disorder and post-traumatic stress disorder. Its AFFIRM-1 Phase 3 trial in social anxiety disorder failed to meet its primary endpoint in October 2025, while secondary endpoints also failed to demonstrate statistically significant differences.

The company subsequently discontinued further development of BNC210 in social anxiety disorder and paused the post-traumatic stress disorder programme. It also began a strategic review intended to identify a merger, asset transaction or other route capable of preserving value for shareholders.

By March 2026, Neuphoria Therapeutics had terminated all but one employee, ended its facility leases and cancelled or paused its internal research activities. This leaves Scancell Holdings with relatively little operating infrastructure to integrate, which could simplify the corporate combination.

The principal attractions are Neuphoria Therapeutics’ Nasdaq listing, cash and remaining partnered assets. The company held approximately US$19.4 million of cash and US$20.1 million of working capital at March 31, with its reduced operating structure expected to preserve cash beyond the fourth quarter of its 2027 financial year.

Neuphoria Therapeutics also retains a partnership with Merck & Co. involving clinical candidates for cognitive impairment associated with Alzheimer’s disease and other central nervous system conditions. The collaboration has previously generated a US$15 million milestone payment and contains potential future milestone and royalty economics, although the timing and probability of additional payments remain uncertain.

The proposed acquisition is therefore not simply a purchase of an empty quotation. Neuphoria Therapeutics remains an operating public company with cash, contractual rights, intellectual property and legacy obligations. However, its current market value of approximately US$21.5 million sits only modestly above its reported cash balance, suggesting investors assign limited value to the remaining pipeline following the AFFIRM-1 failure.

Scancell Holdings must disclose how those assets will be treated after completion. Management could retain selected partnered interests, seek to license BNC210, dispose of non-core programmes or concentrate almost entirely on the Scancell Holdings oncology portfolio.

Can Neuphoria’s US$19.4 million cash materially fund the iSCIB1+ Phase 3 study?

Neuphoria Therapeutics’ cash could extend the enlarged group’s runway and help support the initial stages of the iSCIB1+ Phase 3 programme. It is unlikely to remove the need for a much larger financing package, which explains why Scancell Holdings is discussing equity and debt funding alongside the proposed acquisition.

Scancell Holdings held £8.6 million of cash at October 31, 2025 and received a further £3 million in research and development tax credits after the period ended. The company had used £7.2 million in operating activities during the preceding six months and expected its existing runway to extend only into the second half of 2026.

The balance sheet also contained £18.2 million of convertible loan notes scheduled for repayment or potential conversion during the second half of 2027. Those obligations will need to be considered alongside the capital required for Phase 3 development.

Combining Neuphoria Therapeutics’ cash with Scancell Holdings’ resources could provide an important bridge through trial preparation, regulatory activity, manufacturing and site initiation. Transaction costs, legacy liabilities and the need to retain an operating reserve mean not every dollar held by Neuphoria Therapeutics will be available for clinical spending.

A global registrational study will require patient recruitment across numerous centres, clinical monitoring, drug manufacturing, data management and regulatory work. Scancell Holdings has not disclosed the expected total budget or the amount currently under negotiation.

The concurrent financing talks indicate that the company recognises the scale of the requirement. Neuphoria Therapeutics can strengthen the package, but it is not the entire package.

The most attractive outcome would combine Neuphoria Therapeutics’ cash with new equity, appropriately structured debt and potentially a pharmaceutical partnership. That would spread the development risk rather than forcing existing SCLP investors to fund the full trial through one deeply discounted share issue.

Why is the iSCIB1+ clinical case strong enough to justify a major corporate transaction now?

iSCIB1+ is Scancell Holdings’ most advanced ImmunoBody cancer immunotherapy and is being developed in combination with nivolumab and ipilimumab for previously untreated advanced melanoma. The therapy is intended to stimulate tumour-specific immune responses and improve the durability of existing checkpoint-inhibitor treatment.

The completed SCOPE Phase 2 programme enrolled 140 patients. Scancell Holdings reported progression-free survival of 77% at 20 months within the biomarker-selected target population, compared with 43% reported at the same point for nivolumab and ipilimumab in a separate pivotal study.

The difference exceeding 30 percentage points is clinically interesting, particularly because the selected human leukocyte antigen population is estimated to represent approximately 80% of melanoma patients. The United States Food and Drug Administration has cleared the Phase 3 investigational new drug application and granted Fast Track designation.

Those achievements have reduced regulatory and development uncertainty, but they have not established that iSCIB1+ improves outcomes over checkpoint inhibitors in a controlled comparison. SCOPE was an open-label Phase 2 study, while the standard-of-care benchmark comes from historical trial data rather than a randomised control arm within the same study.

Patient characteristics, follow-up periods and trial conditions can influence cross-study comparisons. The proposed Phase 3 trial must confirm whether the apparent progression-free survival advantage remains present when iSCIB1+ and standard treatment are evaluated under a registrational design.

That distinction explains both the opportunity and the financing challenge. The Phase 2 results are strong enough to justify a pivotal programme and attract investor attention, but not strong enough to remove clinical risk.

Additional progression-free survival and early overall-survival data are expected during the first half of 2027. These results could strengthen the clinical rationale while Phase 3 recruitment is under way, although weaker maturation would place pressure on both valuation and financing.

How could equity and debt financing reshape Scancell Holdings’ ownership and balance-sheet risk?

The largest missing detail is the exchange ratio. Scancell Holdings has not disclosed how many new shares Neuphoria Therapeutics investors would receive, what percentage of the enlarged company they would own or how the transaction would value each side.

Scancell Holdings’ equity market value is several times larger than Neuphoria Therapeutics’ current market capitalisation, suggesting existing SCLP shareholders would probably retain majority economic ownership before the associated fundraising. That outcome remains an inference until binding terms are published.

The concurrent equity financing could create more significant dilution than the merger itself. New United States and United Kingdom investors may demand a discount, warrants or other incentives in exchange for funding an expensive Phase 3 programme with no guaranteed clinical outcome.

Debt financing could reduce immediate equity issuance but would introduce repayment obligations, interest expense and potentially restrictive covenants. Biotechnology debt can also include warrants, milestone conditions or security over intellectual property, meaning it is not always as non-dilutive as the headline label suggests.

Scancell Holdings already has convertible notes due in 2027. Adding conventional or structured debt before resolving those instruments could create a more complicated balance sheet and increase the importance of clinical timelines.

Management must therefore optimise the entire package rather than simply celebrate a Nasdaq listing. A transaction that raises enough capital to complete Phase 3 at a manageable cost could substantially de-risk the programme. A smaller financing that funds only the first part of the study could postpone rather than solve the dilution problem.

Investors will need a detailed sources-and-uses schedule showing Neuphoria Therapeutics’ available cash, transaction expenses, new equity, debt proceeds, trial expenditure and the reserve required for the rest of Scancell Holdings’ portfolio.

What does the SCLP share-price decline reveal about investor expectations for the merger?

SCLP shares closed at 18.4 pence on June 26, down 3.16% from the previous closing price of 19 pence. The shares were approximately 10.2% below their June 19 close of 20.5 pence and 20% lower than the 23 pence recorded on May 26.

The stock remains within a wide 52-week range of 7.86 pence to 29.5 pence. At the latest close, Scancell Holdings had a market capitalisation of approximately £191 million, around 38% below the annual high but more than double the 52-week low.

The negative reaction does not necessarily mean investors oppose a Nasdaq listing. It more likely reflects uncertainty around the price, dilution and financing conditions. Scancell Holdings confirmed the discussions in response to market speculation rather than announcing a completed agreement, leaving investors with strategic direction but few transaction economics.

Some shareholders may also question why the company needs to acquire another biotechnology company rather than complete a direct listing or secure a conventional pharmaceutical partnership. Neuphoria Therapeutics’ failed Phase 3 programme creates an unhelpful first impression, even though its cash and Nasdaq position may be more relevant than BNC210 to the transaction.

NEUP shares ended the United States session at US$4.57, valuing Neuphoria Therapeutics at approximately US$21.5 million. That valuation sits close to reported cash, highlighting that the market currently treats Neuphoria Therapeutics primarily as a strategic transaction candidate with residual asset optionality.

Published SCLP analyst coverage remains thin. The two-analyst consensus target is approximately 31 pence, but such a limited sample should not be treated as broad institutional validation, particularly before the merger and fundraising terms are known.

In our view, the share-price weakness is rational caution rather than a verdict against the strategy. The industrial logic is credible, but shareholders cannot assess value until they know how much of the enlarged company they will own and whether the proposed financing is sufficient to reach the decisive Phase 3 readout.

Could a Nasdaq listing improve valuation without solving Scancell Holdings’ execution challenges?

United States biotechnology investors are accustomed to valuing clinical-stage companies around regulatory milestones, trial design, addressable populations and probability-adjusted commercial outcomes. This could provide Scancell Holdings with a more natural investor base than the broader AIM market.

Nasdaq may also improve liquidity, research coverage and access to specialist funds that cannot or do not invest materially in AIM securities. A larger United States profile could support pharmaceutical partnering and recruitment of clinical, regulatory and commercial leadership.

A United States quotation does not guarantee a higher valuation. Nasdaq contains hundreds of biotechnology companies trading near or below cash after clinical failures, financing setbacks or extended development timelines. Neuphoria Therapeutics itself is an excellent reminder that an American ticker is not a scientific force field.

Scancell Holdings will still need to start Phase 3 on schedule, recruit patients, control costs, maintain drug supply and produce data capable of supporting approval. Investors will judge the company primarily on those outcomes rather than the exchange on which the shares trade.

The enlarged group will also incur higher reporting, governance, insurance and investor-relations costs. Maintaining both AIM and Nasdaq listings could increase complexity further, although the company has not yet disclosed its intended long-term listing structure.

The strongest case for Nasdaq is therefore capital access, not cosmetic prestige. The transaction creates value only if the United States platform helps Scancell Holdings finance iSCIB1+ on better terms than those available through AIM alone.

How would Neuphoria’s remaining assets and liabilities fit within the enlarged oncology company?

Neuphoria Therapeutics’ residual portfolio sits outside Scancell Holdings’ oncology focus. BNC210 addresses neuropsychiatric disorders, while the Merck & Co. partnership involves central nervous system programmes. Scancell Holdings concentrates on active cancer immunotherapies and tumour-targeting antibodies.

Maintaining unrelated internal development programmes would spread management attention and capital across therapeutic areas with little operating overlap. This appears unlikely given Neuphoria Therapeutics’ decision to pause research and reduce its workforce to one employee.

The partnered Merck & Co. assets could be retained as financial interests requiring limited direct spending. Future milestone or royalty payments would provide useful non-dilutive capital if the programmes advance, but they should be treated as contingent upside rather than a reliable funding source.

BNC210 presents a more difficult decision. Restarting the post-traumatic stress disorder programme would require new capital and rebuilding development capabilities. A sale, licence or external partnership may fit the enlarged company better than internal development.

Neuphoria Therapeutics’ intellectual property, corporate obligations and contingent liabilities will form part of due diligence. Scancell Holdings must ensure that the cash being acquired is not offset by restructuring costs, legal exposures, milestone obligations or other commitments.

The merger is likely to work best when Neuphoria Therapeutics provides a clean Nasdaq structure, cash and selected economic rights, while Scancell Holdings supplies the active management team and primary clinical strategy. Trying to preserve every legacy asset would make the enlarged group harder to understand and more expensive to operate.

Which milestones will determine whether the Scancell and Neuphoria transaction creates value?

The first milestone will be definitive merger terms. Investors need the exchange ratio, ownership percentages, board structure, listing arrangements and treatment of Neuphoria Therapeutics’ remaining assets before they can judge whether the acquisition price is reasonable.

The second will be the associated financing package. Scancell Holdings must disclose the equity price, debt terms, gross proceeds, expected runway and whether the funding covers the entire Phase 3 programme or only its initial stages.

Shareholder approvals, Securities and Exchange Commission documentation and Nasdaq clearance will provide the next tests. Any delays could affect the planned second-half 2026 start of the iSCIB1+ registrational trial.

Trial initiation will be the most important operational milestone. Regulatory clearance and Fast Track designation have already been obtained, leaving financing, site activation, manufacturing and patient recruitment as the principal near-term requirements.

Further SCOPE progression-free survival and early overall-survival data in the first half of 2027 will influence confidence while the pivotal trial proceeds. The company must also address the £18.2 million of convertible loan notes due later that year.

A pharmaceutical partnership remains an important alternative or complement to the proposed financing. An agreement containing meaningful upfront cash and shared development costs could reduce leverage and dilution while providing external scientific validation.

The reverse merger could solve several problems at once by adding cash, creating Nasdaq access and improving Scancell Holdings’ visibility with United States investors. It could also create new problems if the exchange ratio is generous to Neuphoria Therapeutics shareholders, the financing is inadequate or debt compounds the existing convertible obligations.

The announcement has opened a credible route towards Phase 3. The decisive question is no longer whether Scancell Holdings can reach Nasdaq, but what existing shareholders must surrender to get there.

Key takeaways on the Scancell reverse merger, iSCIB1+ funding and SCLP outlook

• Scancell Holdings is in advanced discussions to acquire Neuphoria Therapeutics through an all-share transaction that could create a Nasdaq listing.
• The proposed acquisition remains subject to final terms, definitive documents, shareholder approvals and regulatory processes.
• Neuphoria Therapeutics held US$19.4 million of cash and US$20.1 million of working capital at March 31, 2026.
• Neuphoria Therapeutics discontinued its social anxiety programme and paused its post-traumatic stress disorder programme after the AFFIRM-1 Phase 3 failure.
• Scancell Holdings is negotiating separate equity and debt financing because Neuphoria Therapeutics’ cash alone is unlikely to fund the global iSCIB1+ Phase 3 study.
• iSCIB1+ achieved 77% progression-free survival at 20 months in the selected Phase 2 population, but the comparison with standard care was historical rather than randomised.
• The United States Food and Drug Administration has cleared the registrational study and granted iSCIB1+ Fast Track designation.
• Scancell Holdings held £8.6 million of cash at October 31, 2025 and has £18.2 million of convertible loan notes due in 2027.
• SCLP closed at 18.4 pence, down approximately 10.2% over five trading sessions and 20% over one month.
• Exchange ratio, fundraising price, debt terms and the amount of Phase 3 development covered will determine whether the transaction creates shareholder value.